Regenerative Therapies for Parkinson's Disease: An Update.
View / Open Files
Publication Date
2018-08Journal Title
BioDrugs
ISSN
1173-8804
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
4
Pages
357-366
Language
eng
Type
Article
Physical Medium
Print
Metadata
Show full item recordCitation
Stoker, T., & Barker, R. (2018). Regenerative Therapies for Parkinson's Disease: An Update.. BioDrugs, 32 (4), 357-366. https://doi.org/10.1007/s40259-018-0294-1
Abstract
Parkinson's disease is the second most common neurodegenerative disorder. It is characterised by a typical movement disorder that occurs in part because of the selective degeneration of the dopaminergic neurons of the substantia nigra pars compacta. Current treatment for the motor disorder of Parkinson's disease consists of dopaminergic medications, but these come with significant adverse effects, themselves an important part of the clinical course of Parkinson's disease, particularly in advanced stages. Therefore, treatment is needed that can restore dopaminergic tone in the striatum in a physiological and targeted manner to avert these side effects. A number of potential regenerative treatments have been developed with a view to achieving this. Following decades of optimisation and development of stem-cell-based treatments and viral gene delivery, clinical trials are on the horizon. For these treatments to be widely useful, they must be clinically effective, cost efficient and safe, and a number of practical aspects regarding storage and delivery of treatment must be optimised. Many barriers have been overcome, and the field of regenerative medicine for Parkinson's disease is now increasingly focussed on how these treatments will be delivered, demonstrating the significant progress that has been made and the optimism surrounding these approaches.
Keywords
Humans, Parkinson Disease, Dopamine, Stem Cell Transplantation, Regenerative Medicine, Genetic Vectors, Patient Selection, Clinical Trials as Topic, Genetic Therapy
Sponsorship
The authors acknowledge financial support from the following organisations: Medical Research Council, Wellcome Trust Stem Cell Institute (Cambridge), National Institute for Health Research Biomedical Research Centre, and the Cure Parkinson’s Trust
Funder references
Medical Research Council (MC_PC_12009)
Identifiers
External DOI: https://doi.org/10.1007/s40259-018-0294-1
This record's URL: https://www.repository.cam.ac.uk/handle/1810/280538
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.